Avacta Group Regulatory News (AVCT)

March 28 2024

Avacta Group plc

("Avacta" or the "Group" or the "Company")

Investor Webinar

Avacta Group plc (AIM: AVCT), a life sciences company developing innovative, targeted oncology drugs and powerful diagnostics, is pleased to announce that Chief Executive Officer Dr. Alastair Smith will be hosting a webinar on Wednesday, 10 April 2024 at 5:30pm (BST).

The webinar will cover the Company's updated clinical data from the first-in-human Phase 1 trial of AVA6000, the first of the Company's pre|CISION? peptide drug conjugates that targets chemotherapy to the tumor, which are to be presented at the 2024 American Association for Cancer Research Annual Meeting, taking place in San Diego, California from 5-10 April 2024. The updated clinical data will be presented in the Phase 1 Clinical Trials 2 Poster Session on 9 April 2024.

There will be a Q&A session for investors after the presentation and questions can be submitted pre-event as part of the registration process.

You can register for the event by using the following link:

https://www.turnerpope.com/register/

We are delighted to announce that the webinar will be chaired by news and corporate events presenter Katie Pilbeam (www.katiepilbeam.com) and hosted by Turner Pope Investments.

-Ends-

For further information from Avacta Group plc, please contact:

About Avacta Group plc - https://www.avacta.com

Avacta Group is a UK-based company focused on improving healthcare outcomes through targeted cancer treatments and diagnostics.

Avacta has two divisions: an oncology biotech division harnessing proprietary therapeutic platforms to develop novel, highly targeted cancer drugs, and a diagnostics division, focused on supporting healthcare professionals and broadening access to testing. Avacta's two proprietary platforms, Affimer® and pre|CISION? underpin its cancer therapeutics whilst the diagnostics division leverages the Affimer® platform to drive competitive advantage in its markets.

The pre|CISION? platform modifies chemotherapy to be activated only in the tumor tissue, reducing systemic exposure and toxicity. This is achieved by harnessing an enzyme called FAP which is highly upregulated in most solid tumors compared with healthy tissues, turning chemotherapy into a "precision medicine". The lead pre|CISION? programme, AVA6000 a tumour activated form of doxorubicin, is in Phase 1 studies and has shown dramatic improvement in safety compared with standard doxorubicin, and early signs of clinical activity.

To register for news alerts by email go to https://avacta.com/investors/investor-news-email-alerts/